During the same quarter last year, the firm earned ($0.99) EPS. The business had revenue of $38.78 million for the quarter, compared to analyst estimates of $33.52 million. Blueprint Medicines had a negative return on equity of 80.09% and a negative net margin of 273.24%. The biotechnology company reported ($2.65) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.73) by $0.08. Get Blueprint Medicines alerts:īlueprint Medicines ( NASDAQ:BPMC – Get Rating) last announced its earnings results on Thursday, February 16th. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $76.28. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. Finally, Raymond James reduced their target price on Blueprint Medicines from $115.00 to $85.00 and set a “strong-buy” rating for the company in a research note on Friday. Oppenheimer lowered Blueprint Medicines from an “outperform” rating to a “market perform” rating in a research report on Wednesday, November 2nd. Wells Fargo & Company raised Blueprint Medicines from an “underweight” rating to an “equal weight” rating and set a $41.00 price target on the stock in a research report on Monday, January 2nd. SVB Leerink lowered their price target on Blueprint Medicines from $57.00 to $52.00 and set a “market perform” rating on the stock in a research report on Wednesday, November 2nd. Wedbush lowered their price target on Blueprint Medicines from $120.00 to $106.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 2nd. Other research analysts have also issued research reports about the company. HC Wainwright’s price target would suggest a potential upside of 51.45% from the company’s previous close. They presently have a $70.00 price objective on the biotechnology company’s stock. Blueprint Medicines ( NASDAQ:BPMC – Get Rating)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research report issued on Friday, Benzinga reports.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |